Olverembatinib 20mg

DRUG2 trials

Sponsors

Ascentage Pharma Group Inc., Qian Jiang

Conditions

Chronic Myeloid LeukemiaOlverembatinibPharmacokinetic

Phase 1

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

RecruitingNCT07282093

Ascentage Pharma Group Inc.Olverembatinib, Pharmacokinetic

Start: 2025-11-11End: 2026-10-31Target: 48Updated: 2025-12-23

Unknown Phase

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Enrolling by invitationNCT07383298

Qian JiangChronic Myeloid Leukemia

Start: 2025-12-16End: 2030-12-31Target: 100Updated: 2026-02-03